BeiGene Reports Second Quarter 2016 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BeiGene Reports Second Quarter 2016 Financial Results

WALTHAM, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported business highlights and financial results for the second quarter of 2016.

“We are pleased with the progress that we have made in our clinical programs and business operations for the first half of 2016,” commented John V. Oyler, Founder, Chief Executive Officer, and Chairman. “We have presented clinical data on all four of our clinical stage assets that we believe have demonstrated proof of concept for each. We have also initiated clinical trials for two proprietary combinations involving BGB-A317, our PD-1 antibody. In addition, we are now in the clinic in China with BGB-283, a RAF dimer inhibitor, and BGB-3111, a BTK inhibitor, and we anticipate receiving approvals to initiate clinical trials in China for our remaining candidates. In the second half of 2016, we anticipate clinical updates on our lead compound BGB-3111, and we look forward to continuing our momentum.”

Second Quarter 2016 and Recent Business Highlights

Clinical Programs:

BGB-3111 , a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK)

  • Initiated a global combination trial of BGB-3111 with BGB-A317, our PD-1 antibody.
  • Initiated the dose-expansion phase of the combination study with the anti-CD20 antibody, obinutuzumab.
  • Initiated Phase I trial of BGB-3111 in China.
  • Continued enrollment in the multi-indication dose-expansion phase of the BGB-3111 monotherapy trial in Australia, New Zealand, Korea, and the United States.
  • Received orphan drug designations from the U.S. Food and Drug Administration for chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom’s macroglobulinemia.

BGB-A317 , a humanized monoclonal antibody against the immune checkpoint receptor PD-1

  • Presented initial clinical data from the Phase 1 dose-escalation monotherapy trial in advanced solid tumors at the 2016 American Society of Clinical Oncology Annual Meeting.
  • Continued enrollment in the dose-expansion phase of a Phase 1 monotherapy trial in multiple indications.
  • Continued enrollment in the global combination study of BGB-A317 and BGB-290, our PARP inhibitor, in advanced cancer patients.

BGB-290 , a highly potent and selective PARP inhibitor

  • Initiated the dose-expansion phase of a Phase 1 monotherapy trial.
  • Continued enrollment in a Phase 1 combination study of BGB-290 and BGB-A317.

Expected Upcoming Milestones

BGB-3111 (BTK Inhibitor)

  • Update data from the ongoing Phase 1 monotherapy study in the second half of 2016, including a presentation at the 9th International Workshop on Waldenström’s Macroglobulinemia and Symposium on Advances in Multiple Myeloma on October 7, 2016 in Amsterdam.
  • Present clinical combination data in 2017.
  • Initiate global registration program in 2016, pending feedback from regulatory authorities.

BGB-A317 (PD-1 Antibody)

  • Continue and expand combination studies in 2016.
  • Present updated data from the ongoing Phase I study in 2016 or 2017.
  • Present clinical combination data in 2017.

BGB-290 (PARP Inhibitor)

  • Present updated Phase 1 monotherapy study data in 2017.
  • Present data from the combination study with BGB-A317 in 2017.

BGB-283 (RAF Dimer Inhibitor)

  • Present dose-expansion data at a medical conference in first half of 2017.

Second Quarter 2016 Financial Results

Cash, C ash Equivalents , and S hort-term I nvestments were $226.62 million as of June 30, 2016, compared to $100.49 million as of December 31, 2015. The increase reflects net initial public offering (IPO) proceeds received in the first quarter of 2016, partially offset by cash used in operating activities for the six months ended June 30, 2016.

The cash used in operations for the quarter and six months ended June 30, 2016 were $19.26 million and $39.10 million, respectively, as compared to $6.67 million and $13.20 million, respectively, for the same periods in 2015.  The increase was primarily attributable to higher operating expense and a decrease in accounts payable. Capital expenditure for the quarter and six months ended June 30, 2016 were $5.46 million and $8.76 million, respectively, as compared to $0.61 million and $1.03 million, respectively, for the same periods in 2015.

Revenue for the three months ended June 30, 2016 was $0.39 million, compared to $1.38 million for the three months ended June 30, 2015. The decrease in revenue for the second quarter was primarily attributable to revenue that was no longer being recognized for BGB-290 after the repurchase of its ex-China rights from Merck KGaA, Darmstadt, Germany in October 2015.    

Research & D evelopment (R&D) E xpenses for the three months ended June 30, 2016 were $21.12 million, compared to $6.74 million for the three months ended June 30, 2015. The increase in R&D expenses was primarily attributable to increased spending on clinical activities for BGB-3111, BGB-A317, BGB-290, and BGB-283. In addition, R&D-associated stock option expenses were $0.74 million for the three months ended June 30, 2016 and $0.89 million for the three months ended June 30, 2015.

G eneral & A dministrative (G&A) E xpenses for the three months ended June 30, 2016 were $3.90 million, compared to $1.21 million for the three months ended June 30, 2015. The increase in G&A expenses was primarily attributable to salary, bonus and share-based compensation as a result of increased headcount and professional service fees to support growing operations. In addition, G&A-associated stock option expense was $0.54 million for the three months ended June 30, 2016, compared to $0.02 million for the three months ended June 30, 2015.

Net L oss for the quarter ended June 30, 2016 was $24.12 million, compared to $5.64 million for the same period ended June 30, 2015. Net loss for the six months ended June 30, 2016 was $46.13 million, compared to $15.85 million for the six months ended June 30, 2015.

Financial Summary

   
Select C onsolidated B alance S heet Data (U.S. GAAP)  
(Amounts in thousands of U.S. Dollars)  
       
    June 30, 201 6 (unaudited)   December 31, 201 5 (audited)  
Cash, cash equivalents, and short‑term investments   $ 226,619 $   100,486    
Prepaid expenses and other current assets   6,135     5,783    
Property and equipment, net   9,752     6,612    
Total assets   251,230     116,764    
           
Accounts payable   6,071     8,980    
Senior promissory note   —     14,598    
Long-term bank loan   10,553     6,188    
Total shareholders’ equity (deficit) $ 220,047 $   (101,765 )  
 
C onsolidated Statements of Operations (U.S. GAAP)
(Amounts in thousands of U.S. Dollars, except for number of ADSs and per ADS data) (unaudited)
       
    Three Months Ended June 30,   Six Months Ended June 30,
      2016       2015       2016       2015  
Collaboration revenue $   393   $   1,380   $   1,070   $   2,759  
Operating expenses:                
Research and development     (21,117 )     (6,737 )     (38,994 )     (16,796 )
General and administrative     (3,904 )     (1,208 )     (7,038 )     (2,340 )
Total operating expenses     (25,021 )     (7,945 )     (46,032 )     (19,136 )
Loss from operations     (24,628 )     (6,565 )     (44,962 )     (16,377 )
Interest income (expense)     121       136       411       (14 )
Other income (expense)     518       788       (1,395 )     538  
Loss before income tax expense     (23,989 )     (5,641 )     (45,946 )     (15,853 )
Income tax expense     (135 )     -       (179 )     -  
Net loss $   (24,124 ) $   (5,641 ) $   (46,125 ) $   (15,853 )
Net loss per ADS, basic and diluted $   (0.73 ) $   (0.68 ) $   (1.66 ) $   (1.90 )
Weighted-average number of ADS used in net loss per ADS calculation - basic and diluted      32,903,593       8,349,608       27,761,107       8,347,751  
 
C onsolidated Statements of Comprehensive Loss (U.S. GAAP)
(Amounts in thousands of U.S. Dollars) (unaudited)
       
  Three Months Ended June 30 ,   Six Months Ended June 30,
      2016       2015       2016       2015  
Net loss $   (24,124 ) $   (5,641 ) $   (46,125 ) $   (15,853 )
Other comprehensive income/(loss), net of tax of nil:                
Foreign currency translation adjustments     (486 )     (32 )     (390 )     (81 )
Unrealized holding gain (loss)     275       (365 )     736       (421 )
Comprehensive loss $   (24,335 ) $   (6,038 ) $   (45,779 ) $   (16,355 )

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 250 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s financial condition; results of operations and business outlook; the sufficiency of its cash, cash equivalents and short-term investments; momentum of its product pipeline as well as the advancement of, and anticipated development and regulatory milestones and plans related to, BeiGene’s drug candidates and clinical trials, including commencing registration and combination trials and providing data readouts and updates for its clinical candidates.  Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; BeiGene's ability to achieve market acceptance in the medical community necessary for commercial success; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct preclinical studies and clinical trials; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in the BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission.  All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 ir@beigene.com media@beigene.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading

Top 5 Most Recently Viewed Articles

3Srobotics Breaks Ground with North American Debut

Updated Category News Views 204

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...

Continue Reading
Uganda Plans Major Spending Cuts and Reduced Borrowing for 2025

Updated Category News Views 912

Uganda's government announced a hefty shift in its fiscal playbook back in 2024, aiming to cut spending by over 20% and slash domestic borrowing by more than half for the upcoming 2025/26 fiscal year. This wasn’t just some routine budgetary tweak; it was a necessary maneuver amidst growing alarm about the nation's spiraling public debt. You know these moves grab...

Continue Reading
Vivos Therapeutics to Share Q1 2025 Results and Updates Soon

Updated Category News Views 257

Vivos Therapeutics Prepares for Q1 2025 Financial Disclosure Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering company in the medical devices sector, is gearing up to release its financial results for the first quarter of 2025. This announcement is anticipated to take place following the market's closure on a Thursday in May 2025. The management team is set to hold a...

Continue Reading
Join XBP Global for the Annual Turkey Trot This Thanksgiving

Updated Category News Views 217

XBP Global Welcomes You to the 11th Annual Turkey Trot XBP Global Holdings, Inc. (NASDAQ: XBP) is thrilled to invite the community to the 11th Annual Palisades Turkey Trot, a cherished tradition returning this Thanksgiving morning. Held at Palisades Green, this year's event promises excitement with new 5K and 10K courses that enhance the festive atmosphere of the...

Continue Reading
Market Reaction to CEO Departure and Boot Barn's Strong Quarter

Updated Category News Views 317

Boot Barn Stock Forecast Amid CEO Transition and Solid Performance In the latest developments regarding Boot Barn (NYSE: BOOT), analysts at Craig-Hallum have made notable adjustments to their stock price outlook. The price target has been revised to $160 from a previous $162, maintaining a Hold rating. The adjustments come in light of the company's impressive performance...

Continue Reading